Business Wire

NY-ESTÉE-LAUDER

Share
The Estée Lauder Companies Announces New Equity and Engagement Center of Excellence

The Estée Lauder Companies (NYSE:EL) announced today that it has established a new Equity and Engagement Center of Excellence (COE). The creation of this new capability underscores The Estée Lauder Companies’ (ELC) core values and commitments to build greater equity and representation within every aspect of its business, from its employees to its consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005218/en/

The Equity and Engagement COE will be led by Nicole Monson , who has been appointed Senior Vice President, Equity and Engagement. Nicole will report directly to Michael O’Hare, Executive Vice President, Global Human Resources.

The events of 2020 and the movement around racial equality have placed a necessary spotlight on every company’s responsibility to take action to advance equal representation, advocacy and inclusion across their organizations. From examining and evolving how the company engages with employees around the world, to enabling greater collaboration across its brands, regions and functions, ELC remains dedicated to purposeful, strategic and accelerated action to drive lasting change.

Building upon ELC’s existing Commitment to Act on Racial Equity , actions on pay equity and other activities to date, the creation of the Equity and Engagement COE signals ELC’s investment in a focused and holistic approach to drive sustainable progress and advance the company’s diverse talent through deep engagement, career advancement, development programs, hiring practices and beyond.

“Our collective vision is to be the most inclusive, equitable and diverse global prestige beauty company for our employees and consumers alike. This important new capability will enhance employee engagement and build greater equity across the business today, while also providing a strategic platform to expand and scale this work into the future,” said Fabrizio Freda, President and Chief Executive Officer . “We know that authentic change takes time, dedication and a clear strategy, and we will continue to devote focused and meaningful resources toward accelerating this goal.”

“Since our company’s founding, our talented employees have been at the center of our business and the most important driver of our success. While we are proud of the progress we have made as a company thus far, we are committed to driving equity and engagement for the long-term,” said William P. Lauder, Executive Chairman . “Nicole’s deep experience and extensive knowledge of Human Resources and the global legal environment, combined with her demonstrated ability to positively influence ELC’s culture, have been invaluable to the company. I look forward to her continued leadership at the helm of this new Center of Excellence.”

As Senior Vice President, Equity and Engagement, Nicole will be an important member of ELC’s Senior Leadership Team and she will work across all areas of the business to develop the company’s long-term Equity and employee Engagement strategy and enterprise-wide capabilities. She will lead the development and implementation of proactive Equity and Engagement initiatives to create a workforce that is more representative and responsive to people of all backgrounds, where all have an opportunity to succeed.

The Equity and Engagement COE was designed to be a strategic and complementary enterprise-wide partner to ELC’s other leaders and business units focused on ESG-related matters, including Human Resources, the Inclusion, Diversity & Equity (IDE) COE, Global Communications, Global Citizenship and Sustainability (GCCS), Global Public Affairs, and beyond. In this spirit, Nicole will collaborate closely with Human Resources leaders and the IDE COE to develop programs designed to ensure fair, inclusive, and equitable treatment of employees around the world with emphasis on addressing conflict and implementing support systems for employees of color, ensuring equitable compensation, application of policies and access to career paths and ensuring the execution of ELC’s equity and engagement vision and strategy. Additionally, Nicole will lead the company’s Racial Equity Initiative, which includes finalizing and implementing a strategy to ensure ELC achieves its Racial Equity Commitments.

Nicole has an extensive proven track record of providing business partners with strategic legal counsel on a wide range of employment and compliance topics, a background that will serve her well in her new role. In her most recent position as Senior Vice President, Deputy General Counsel, Global Employment, Ethics and Legal Privacy, Nicole oversaw the Employment Law, Ethics and Legal Privacy teams and worked to advance the Legal strategy for employment, ethics and privacy globally to protect the company’s interests and mitigate risks associated with new laws and regulations, growth of digital platforms, new global acquisitions and an increased regulatory environment. Since joining the company in 2014 as Vice President, Employment Counsel, her role has continuously expanded and evolved with new responsibilities.

Nicole’s influence on ELC’s organizational culture has extended far beyond her official role and responsibilities. As a member of ELC’s Diversity Council, as well as ELC’s ‘Network of Black Leaders & Executives’ and ‘Women’s Leadership Network’ Employee Resource Groups, Nicole has long been passionate about promoting a culture of respect, inclusivity and belonging. Recently, she became Executive Sponsor of She’s Howard: Own Your Power , ELC’s partnership with Howard University to support the success of the University’s alumnae through experiential learning, career coaching, professional training and self-empowering mentorship opportunities.

In addition to her many contributions to ELC, Nicole is a highly regarded expert and thought leader. She has been a guest speaker for numerous local and national organizations. Notably, Nicole was also selected for inclusion into the National Black Lawyers Top 100 , an elite network of successful and influential lawyers with reputations for providing excellent legal representation in their respective practice areas.

Nicole has more than 20 years of relevant experience across labor and employment law and compliance. She earned her J.D. from Howard University School of Law and her B.A. from Spelman College.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

ELC-C
ELC-L

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye